ANGIOTENSIN RECEPTOR BLOCKERS IMPROVED CARDIOMYOGENIC TRANSDIFFERENTIATION EFFICIENCY OF HUMAN MARROW-DERIVED MESENCHYMAL STEM CELLS IN VITRO  by Numasawa, Yohei et al.
A19.E183
JACC March 9, 2010
Volume 55, issue 10A
 CARDIAC FUNCTION AND HEART FAILURE 
ANGIOTENSIN RECEPTOR BLOCKERS IMPROVED CARDIOMYOGENIC TRANSDIFFERENTIATION 
EFFICIENCY OF HUMAN MARROW-DERIVED MESENCHYMAL STEM CELLS IN VITRO
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Myocardial Function/Heart Failure---Basic/Molecular--Tissue Engineering
Abstract Category: Myocardial Function/Heart Failure---Basic/Molecular
Presentation Number: 1013-56
Authors: Yohei Numasawa, Shunichiro Miyoshi, Takehiro Kimura, Nobuhiro Nishiyama, Hiroko Tsuji, Naoko Hida, Daisuke Shinmura, Hikaru Nakamizo, 
Ikuko Togashi, Kaoru Segawa, Akihiro Umezawa, Satoshi Ogawa, Keio Univsersity School of Medicine, Tokyo, Japan
Background: Human marrow-derived mesenchymal stem cell (MSC) might not be a good cardiac stem cell source, because of low cardiomyogenic 
transdifferentiation efficiency (CTE) of MSC and modest efficacy of MSC transplantation. However, if they can be improved, MSC may come back to 
be a good stem cell source again. Since angiotensin plays an important role in maintenance of cardiomyocyte homeostasis and angiotensin receptor 
blockers (ARBs) shows favorable effect on patient with cardiovascular disease, we hypothesized that ARB might affect CTE of MSC.
Methods: EGFP-labeled MSCs were co-cultured with murine fetal cardiomyocytes for cardiomyogenic induction (CI). Immediately before CI, 
MSCs were pretreated with 3μM of ARBs (PD123319, valsartan, olmesartan, losartan, candesartan, telmisartan) for 2 weeks. Few days after CI, 
EGFP-positive MSCs start beating. One week after CI, MSCs were stained immunocytochemically, and CTE was defined as the ratio of anti-cardiac 
troponin-I positive cells in the EGFP-positive cells.
Results: MSC-derived cardiomyocteys stained positive for troponin-I (with clear striation pattern) by immunocytochemical method. Pretreatment 
with ARBs significantly increased the CTE (Fig), while PD123319, a specific AT2 receptor blocker, did not affect the CTE.
Conclusions: The pretreatment of MSCs with ARB significantly improved CTE via blockade of AT1 receptor. ARB-activated MSCs can be a promising 
cellular source for cardiac stem cell therapy.
